Genomics, Inc. (NASDAQ:TXG – Get Free Report) has received a consensus recommendation of “Hold” from the seventeen analysts ...

Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...

Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...

10x Genomics' instruments sales fell to $24.35 million from $38.4 million a year ago. This included $10.93 million from Chromium instruments and $13.43 million from Spatial instruments.

Chromium Consumables Revenue (Q4 2024): $97.7 million ... Revenue Guidance (2025): $610 million to $630 million, representing ...

10x Genomics specializes in developing and manufacturing genomics analysis technologies, with a focus on single-cell and spatial genomics. The company's product portfolio includes the Chromium and ...

Chromium consumables revenue was $118.1 million ... Macroeconomic uncertainties could impact spending in academia and biopharma. 10x Genomics delivered strong Q4 2023 results with substantial ...

On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...

10x Genomics specializes in developing and manufacturing genomics analysis technologies, with a focus on single-cell and spatial genomics. The company's product portfolio includes the Chromium and ...